|Day Low/High||36.96 / 37.38|
|52 Wk Low/High||27.88 / 43.08|
We also dissect the S&P 500's record run, check out China's latest economic data and take a skeptical glance at an idea floated by a couple Fed officials.
Two companies in pet pharmaceuticals plan to combine, while two other concerns are worth a look based on developments in their respective spaces.
Especially when healthcare CEOs discus political issues with analysts and reporters.
For investors interested in biotech, there's a lot to choose from, with options ranging from startups with potentially blockbuster new treatments to companies those that have been around the block a few times.
Healthcare giants Johnson & Johnson and Pfizer offer a tough choice for dividend investors seeking the best returns.
Pets can bring significant profits to companies that cater to this niche market.
Selecting the creme de la creme of last year's top dividend dogs generated an average total return of 8.8%.
Pfizer may be done with its two-month correction but the uptrend may not resume right away.
When the stock's inexpensive, hated and devoid of love -- that's when.
What we have seen of late from a number of chip producers really might be interpreted as pre-recessionary.
One of pharma's biggest CEO's talks M&A action on the exchange.
Do we have to run for the hills? Not necessarily.
This is the kind of reversal that happens in a bull market.
We're out in San Francisco this week covering the amazing innovations that so many companies reveal at this annual conference.
Take upbeat outlooks for equities with a grain of salt, and try these sectors to stay safe.
Pfizer pushes higher on price increases.
A retest of the October lows seems almost too obvious but it is hard to dispute the possibility that it may occur.
Pharma could be the best parking spot for your money if the market keeps trending downward.
Shares of the New York City-based pharmaceutical giant are rising on Monday.
Pfizer trades with a trailing PE of 15 and is expected to grow earnings 2% in 2019.
The cancer drug market is expected to grow from a surveyed total value of $78 billion in 2015 to over $110 billion by 2020.
Let's check our indicators.
Eli Lilly's self-policing on drug pricing protects it from the most prominent political pushbacks.
And keep in mind that earnings season is not over, and there's enough juice left to impact the marketplace.